|
시장보고서
상품코드
2148368
종양학 동반진단약 시장 : 제품·서비스별, 기술별, 암 유형별, 최종사용자별, 지역별Oncology Companion Diagnostics Market, By Product and Service, By Technology, By Cancer Type, By End User, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
종양학 동반진단약 시장은 2026년에 54억 7,000만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 110억 2,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 10.6%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 54억 7,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 10.60% | 2033년 시장 규모 예측 : | 110억 2,000만 달러 |
전 세계 종양학 동반진단 시장은 바이오마커를 기반으로 환자를 선별하고 치료법을 결정하는 정밀 종양학 분야에 혁명을 일으키고 있습니다. 유전체학, 단백체학, 분자 검사의 발전으로 인해 유방암, 폐암, 대장암, 전립선암 등 일반적인 암에 대한 표적 치료에 동반 진단의 적용이 확대되고 있습니다.
진단법과 표적 치료의 공동 개발을 통해 동반 진단의 임상적 활용이 확대되고 있으며, 맞춤형 암 치료에서 그 역할이 명확해지고 있습니다. 이러한 검사는 바이오마커에 기반한 암 치료 경로의 증가에 따라 환자 계층화를 개선하고, 치료법 선택에 정보를 제공하며, 치료 성과를 최적화하는 역할을 수행하고 있습니다.
시장 역학
전 세계 종양학 동반 진단 시장은 개인화·정밀 종양학에 대한 수용 확대와 유방암, 폐암, 대장암 및 기타 암에 대한 바이오마커 기반 치료 선택에 대한 의존도 증가에 힘입어 성장하고 있습니다. 차세대 염기서열 분석(NGS) 및 다중 검사 기술의 발전으로 여러 바이오마커의 검출 능력이 향상되어 표적 치료법 결정에 도움을 주고 있습니다.
그러나 암 동반진단 시장의 성장은 높은 개발 및 검증 비용, 복잡한 규제 절차, 지역별 보험 급여 제도의 불확실성 등의 요인에 의해 제약을 받고 있습니다. 그럼에도 불구하고 신흥 시장의 의료 분야 투자 확대, 바이오마커 주도형 치료법 파이프라인의 증가, 진단 결과 해석에 AI 활용 확대 등에는 큰 기회가 존재하고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 규명하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 해설하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트를 제공합니다.
- 본 조사에서는 다음 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 종양학 동반진단 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서에서 얻은 인사이트를 바탕으로 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- 본 ‘전 세계 종양학 동반 진단 시장’ 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 종양학 동반진단 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활하게 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 종양학 동반진단약 시장 : 제품·서비스별, 2021-2033년
제5장 세계의 종양학 동반진단약 시장 : 기술별, 2021-2033년
제6장 세계의 종양학 동반진단약 시장 : 암 유형별, 2021-2033년
제7장 세계의 종양학 동반진단약 시장 : 최종사용자별, 2021-2033년
제8장 세계의 종양학 동반진단약 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고 문헌 및 조사 방법
KSA 26.10.19Oncology Companion Diagnostics Market is estimated to be valued at USD 5.47 Bn in 2026 and is expected to reach USD 11.02 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5.47 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.60% | 2033 Value Projection: | USD 11.02 Bn |
The global oncology companion diagnostics market is revolutionizing the precision oncology arena to choose the patients and decide the treatment on the basis of biomarkers. The applications of companion diagnostics for targeted treatments in common cancers like breast, lung, colorectal and prostate cancers is increasing due to developments in genomics, proteomics and molecular testing.
The co-development of diagnostics and targeted treatments is expanding the clinical use of companion diagnostics and delineating their role in personalized cancer care. These tests serve to better stratify patients, inform treatment selection, and optimize therapeutic outcomes in an increasing number of biomarker-driven oncology treatment pathways.
Market Dynamics
The global oncology companion diagnostics market is driven by the expanding acceptance of personalized and precision oncology and the rising dependence on biomarker-based treatment choices for various cancers such as breast, lung, colorectal, and others. Developments in Next Generation Sequencing (NGS) and multiplex testing have improved detection capabilities for multiple biomarkers and aided in making decisions for targeted therapy.
However, the growth of oncology companion diagnostics market is limited by factors such as high development and validation costs, complex regulatory pathways, and reimbursement uncertainties across regions. Nevertheless, significant opportunities exist in increasing investments in healthcare in emerging markets, rise in the pipeline of biomarker-driven therapies, and growing use of AI for diagnostic interpretation.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global oncology companion diagnostics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Illumina, Inc., Abbott Laboratories, Foundation Medicine, Inc., Guardant Health, Inc., Myriad Genetics, Inc., and bioMerieux S.A.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global oncology companion diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology companion diagnostics market
Market Segmentation
- Product and Service Insights (Revenue, USD Bn, 2021 - 2033)
- Kits and Reagents
- Instruments
- Services
- Technology Insights (Revenue, USD Bn, 2021 - 2033)
- Immunohistochemistry (IHC)
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- In Situ Hybridization (ISH)
- Other Technologies
- Cancer Type Insights (Revenue, USD Bn, 2021 - 2033)
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Cancer Centers
- Diagnostic Laboratories
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Illumina, Inc.
- Abbott Laboratories
- Foundation Medicine, Inc.
- Guardant Health, Inc.
- Myriad Genetics, Inc.
- bioMerieux S.A.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Oncology Companion Diagnostics Market, By Product and Service
- Global Oncology Companion Diagnostics Market, By Technology
- Global Oncology Companion Diagnostics Market, By Cancer Type
- Global Oncology Companion Diagnostics Market, By End User
- Global Oncology Companion Diagnostics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Industry Trends
4. Global Oncology Companion Diagnostics Market, By Product and Service, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Kits and Reagents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Instruments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Oncology Companion Diagnostics Market, By Technology, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Immunohistochemistry (IHC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Next-Generation Sequencing (NGS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Polymerase Chain Reaction (PCR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- In Situ Hybridization (ISH)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Other Technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Oncology Companion Diagnostics Market, By Cancer Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Oncology Companion Diagnostics Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals and Cancer Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Oncology Companion Diagnostics Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agilent Technologies, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- QIAGEN N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Foundation Medicine, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Guardant Health, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Myriad Genetics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- bioMerieux S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
